Source: Arch Therapeutics, Inc. 6/29/18
Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), a developer of innovative materials as hemostatic and wound care devices, today announced the pricing of registered direct offering of 9.1 million units, each unit consisting of a share of the Company’s common stock, and a Series G Warrant (“Series G Warrant”) to purchase 0.75 of a share of our common stock for the combined purchase price of $0.50 per unit. The Series G Warrants have an exercise price of $0.70 per share and are exercisable for a period of five years.
The gross proceeds to Arch from this
offering are approximately $4.5 million before deducting estimated
offering expenses payable by the Company. The offering is expected to
close on or about July 2, 2018, subject to customary closing conditions.
The
securities described above are being offered by Arch pursuant to a
registration statement previously filed with and subsequently declared
effective by the Securities and Exchange Commission (“SEC”)
(File Number 333- 213878) on October 20, 2016. A final prospectus
supplement relating to the offering will be filed with the SEC and, once
filed, will be available on the SEC’s website at http://www.sec.gov.
This
press release shall not constitute an offer to sell or the solicitation
of an offer to buy any of the securities described herein, nor shall
there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Arch Therapeutics, Inc.
Arch
Therapeutics, Inc. is a biotechnology company developing a novel
approach to stop bleeding (hemostasis), control leaking (sealant) and
manage wounds during surgery, trauma and interventional care. Arch is
developing products based on an innovative self-assembling barrier
technology platform with the goal of making care faster and safer for
patients. Arch's development stage product candidates include the AC5™
Topical Gel and the AC5™ Surgical Hemostatic Device.
No comments:
Post a Comment